Strategic acquisition Citrus Health Group recently expanded through the acquisition of The Medicine Group, signaling appetite for growth, expanded capabilities in medical communications, and potential cross-sell opportunities across CNS-focused assets and product launches.

Expansion leadership New senior hires including chief client officer and leadership in market access and client services indicate a focus on client growth, strategic account management, and broader service delivery which can open doors for partnerships that align with marketing, pricing, and evidence-generation needs.

Full-spectrum offerings The firm provides end-to-end commercialization services—from scientific communications to pricing, market access, patient advocacy, and engagement—creating opportunities to position Citrus as a preferred partner for integrated launch programs across diverse therapeutic areas.

Science-to-value emphasis With a clear focus on science-to-value and evidence generation, there are potential sales openings for CRO-like collaborations, advisory engagements, and data-driven promotional and payer-focused programs that support clinical and real-world evidence needs.

Financial scale Reported annual revenue of approximately 100–250 million and a mid-sized employee base position Citrus as a credible strategic collaborator for mid-to-large pharma and biotech clients seeking scalable commercialization and market access solutions.